Xpert® Carba-R
Xpert®Carba-R is a qualitative, on-demand real-time PCR test for the detection and differentiation of KPC, NDM, VIM, OXA-48 and IMP in 48-minutes
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
product image
10 Tests
Unit price
Product is not available for purchase in your region.
Error adding items to cart. If this error persists, please contact Digital Support

The Need

  • Carbapenem resistance results in increased mortality in hospitalized patients and is associated with higher total hospital costs.1
  • Organisms carrying integron and plasmid-encoded carbapenemase enzymes are largely responsible for the rapid spread of carbapenem resistance.2
  • CDC recommends comprehensive infection control measures for patients who are colonized or infected with carbapenemase-producing organisms.3
  • Current test methods lack the sensitivity, ease of use, and rapid results required to respond quickly to the threat of carbapenemase-producing organisms.
(1) Judd WR, et al. Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa–infected patients. American Journal of Infection Control. June 2016. (http://www.sciencedirect.com/science/article/pii/S0196655316303431);
(2) https://wwwnc.cdc.gov/eid/article/17/10/pdfs/11-0655.pdf;
(3) http://www.cdc.gov/hai/pdfs/cre/CRE-guidance-508.pdf

The Solution

Xpert® Carba-R can detect and differentiate the most prevalent carbapenemase gene families in just 48 minutes.
  • Detection and differentiation of high-risk patients with Xpert Carba-R can alert clinicians and infection preventionists (IPs) rapidly to the presence of gene sequences associated with carbapenem non-susceptibility in gram-negative bacteria, including Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii.
  • Rapid detection and differentiation of the blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP gene sequences from pure colonies helps clinicians optimize patient management and direct therapeutic strategy, while testing rectal and perirectal swabs helps IPs design effective infection control measures. Perirectal and rectal swabs are not intended to direct therapeutic strategy.
    • Comprehensive infection control measures should be applied to patients who are colonized or infected with carbapenemase-producing organisms.3
(3) http://www.cdc.gov/hai/pdfs/cre/CRE-guidance-508.pdf